课题基金 / 基金详情

INTRACELLULAR SMALL RNA INHIBITORS OF HIV1

INTRACELLULAR SMALL RNA INHIBITORS OF HIV1
HIV1 细胞内小 RNA 抑制剂
批准号:
6124334
负责人:
DAVID R ENGELKE
金额:
$24.72万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 2001-11-30

项目摘要

项目成果

DAVID R ENGELKE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the Abstract): The intracellular expression of RNA-based inhibitors of HIV-1 functions is potentially a powerful tool by which gene therapy might be used against viral replication. Possible inhibitors include antisense RNAs, catalytic RNAs (ribozymes) designed to cleave viral RNA, or high-affinity RNA ligands (aptamers) designed to bind and inhibit the function of essential viral macromolecules. In preliminary experiments, "decoy" RNAs meant to serve as competitive inhibitors of the essential HIV-1 RNA binding protein Rev have proven to be effective. The potential targets for such RNA inhibitors are not limited to proteins that normally have a high affinity for RNA, however. The advent of in vitro evolution (or SELEX) technology makes possible the selection of a series of high-affinity RNA ligands (aptamers) to multiple epitopes on macromolecular antigens. Simultaneous expression of multiple aptamer inhibitors of an array of viral functions could, in principle, overcome mutational escape by the virus. In the proposed research, the Principal Investigator addresses major problems to be solved using such an approach. These are: (1) identification of additional expression strategies that give efficient synthesis of stable aptamers in diverse subcellular locations in human cells; and (2) matching appropriate expression strategies with existing and newly devised anti-HIV-1 RNAs to allow cells to synthesize their own viral inhibitors in vivo. Expression of anti-HIV-1 aptamers will be tested for the ability to suppress infection in stably transfected cell lines. Effective strategies will be optimized and combinatorial expression of the small RNA inhibitors will be tested for synergistic inhibition of viral infection.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
RNASE P
  • 批准号:
    8365869
  • 项目类别:
  • 资助金额:
    $1.28万
  • 财政年份:
    2011
  • 负责人:
    DAVID R ENGELKE
  • 依托单位:
RNASE P
  • 批准号:
    8171431
  • 项目类别:
  • 资助金额:
    $0.24万
  • 财政年份:
    2010
  • 负责人:
    DAVID R ENGELKE
  • 依托单位:
TAP TAG PULL DOWN OF NOVEL PROTEINS INVOLVED IN TGM SILENCING
  • 批准号:
    8171430
  • 项目类别:
  • 资助金额:
    $0.24万
  • 财政年份:
    2010
  • 负责人:
    DAVID R ENGELKE
  • 依托单位:
Nuclear Organization of RNA Polymerase III Transcription
国内基金
海外基金
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
  • 批准号:
    2026JJ50010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    应站明
  • 依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
  • 批准号:
    2026JJ81091
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘亮
  • 依托单位:
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    程子译
  • 依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
  • 批准号:
    JCZRLH202600588
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: